Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

SSSE:603707
8.38
CNY
+0.04
(+0.48%)
0.26EPS
30.46P/E
13.23BMarket Cap
Apr 29Next Earn
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
SSE:603707
(Shanghai Stock Exchange)

Recent

price

8.38

P/E

ratio

30.46

div

yld

1.87%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.38
0.31
0.35
0.44
0.76
1.4
2.04
2.39
2.33
2.28
2.49
2.42
2.47
2.57
Revenue per Share
0.05
0.04
0.06
0.19
0.21
0.35
0.5
0.66
0.67
0.67
-0.12
0.51
0.36
0.27
Basic EPS, GAAP
0.1
0.11
0.08
-0.27
-0.22
-0.02
-0.79
-0.7
0.15
0.08
0.76
0.61
0.39
- -
Free Cash Flow per Basic Share
0.04
0.03
0.02
0.03
- -
0.06
0.08
0.21
0.12
0.14
0.16
0.13
0.14
0.16
Dividend per Share
0.76
0.77
0.82
0.98
1.31
1.53
1.88
2.36
3.33
3.82
3.59
4.02
4.27
4.34
Book Value per Share
0.75
0.76
0.8
0.95
1.28
1.49
1.72
2.18
3.13
3.61
3.22
3.45
3.46
3.48
Tangible Book Value per Share
1,305
1,339
1,354
1,337
1,467
1,216
1,210
1,221
1,581
1,628
1,579
1,620
1,615
1,582
Basic Weighted Avg Shares
500
416
469
582
1,113
1,700
2,470
2,915
3,687
3,713
3,931
3,924
3,991
4,071
Sales/Revenue/Turnover
15.49
10.94
14.92
24.87
30.76
26.51
27.36
33.49
33.68
27.81
24.5
23.33
14.57
11.09
Operating Margin (%)
9
14
18
37
41
40
45
85
93
140
154
175
243
- -
Depreciation Expense
70
50
88
257
314
425
605
806
1,059
1,091
-189
826
582
425
Net Income, GAAP
13.59
17.29
13.76
5.98
11.79
9.23
10.89
12.9
11.62
8.34
- -
16.73
16.86
20.15
Effective Tax Rate (%)
14.07
12.13
18.68
44.21
28.24
24.97
24.5
27.66
28.73
29.38
-4.82
21.06
14.57
10.45
Profit Margin (%)
729
733
783
881
1,585
1,891
2,255
3,962
4,663
5,589
4,175
4,981
4,315
4,610
Working Capital
6
6
6
6
6
6
6
1,125
475
1,007
519
828
77
312
LT Debt
1,018
1,032
1,093
1,315
2,052
2,421
3,004
3,745
5,403
6,167
5,798
6,488
6,899
7,010
Total Equity
- -
3.82
6.41
11.43
16.19
16.19
16.6
13.39
14.44
12.98
- -
9.67
6.54
4.71
Return on Invested Capital (%)
- -
4.25
7
19.59
16.65
16.87
17.5
15.21
15.73
13.85
- -
10.49
7.05
5.22
Return on Capital (%)
- -
4.93
8.24
21.37
18.67
18.98
22.46
24.1
23.28
18.89
-3.16
13.44
8.68
6.24
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,596
2,487
2,014
LT Borrowings
18
18
258
LT Finance Leases
58
59
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,616
1,616
1,616
Market Capitalization
15,817
11,423
13,232

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
7,895
7,991
7,746
Cash, Cash Equivalents & STI
3,387
3,438
2,777
Accounts Receivable, Net
1,115
1,179
1,218
Inventories
3,030
3,046
2,680
Total Current Liabilities
3,479
3,724
3,136
Payables & Accruals
- -
- -
- -
ST Debt
2,596
2,487
2,014
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.38%
14.14%
6.34%
Free Cash Flow
468.25%
125.23%
-37.39%
Net Income, GAAP
-32.19%
-129.74%
-29.61%
Sales/Revenue/Turnover
26.6%
6.92%
1.71%
Total Cash Common Dividend
244.92%
-2.1%
2.45%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,004
1,138
945
836
3,924
2025
885
1,095
- -
1,065
3,991
2026
929
998
1,080
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.14
0.12
0.14
0.51
2025
0.05
0.13
- -
0.09
0.36
2026
0.06
0.06
0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.11
- -
0.13
2025
0.01
0.12
- -
0.01
0.14
2026
- -
0.13
- -
- -
- -
Business
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (603707.SS), founded in 1998 and headquartered in Nanjing, China, engages primarily in the research, development, production, and sales of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms, with a focus on high-end sterile injectables, heparin products, and biopharmaceuticals serving critical care, oncology, and other therapeutic areas. The company offers core products including heparin sodium APIs and finished preparations such as standard heparin, low molecular weight heparin preparations (enoxaparin sodium injections, dalteparin sodium injections, nadroparin calcium injections), oncology injectables (adalimumab injections, azacitidine, busulfan injections, bendamustine hydrochloride injections, melphalan hydrochloride injections, fluorouracil injections), critical care injectables (eptifibatide injections, carboplatin injections), and CDMO services encompassing small-molecule, macromolecule, and cellular gene therapy; it also provides over 80 USFDA-approved products through partnerships in more than 60 countries, positioning it as one of the largest suppliers of heparin APIs and high-end injectables in the US market with annual exports exceeding $250 million. Nanjing King-Friend operates manufacturing sites accredited by USFDA, EMA, PMDA, and others across injectables and APIs, targeting domestic Chinese pharmaceutical manufacturers for global expansion and international markets including the US, EU, Egypt, and Brazil. Recent developments include USFDA approval for eptifibatide injection by subsidiary Hong Kong King-Friend in May 2024; NMPA approval and USFDA submission for subsidiary Kindos' bortezomib for injection in April 2024; first-time US export of cetrorelix acetate for injection with Livzon Group in April 2024; Egyptian approval for enoxaparin sodium injection in March 2024; and an exclusive commercial licensing agreement with Meitheal Pharmaceuticals for YUSIMRY, a Humira biosimilar, announced in late 2024, alongside ongoing collaborations for overseas sales such as with Nanjing King-Friend for JZB33 regulatory applications and marketing in the US.